Title:
IMMUNOSUPPRESSANT IN MRNA DOSAGE FORM AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING TUMORS
Document Type and Number:
WIPO Patent Application WO/2022/120560
Kind Code:
A1
Abstract:
An immunosuppressant in an mRNA dosage form and an application thereof in the preparation of a medicament for treating tumors, belonging to the technical field of tumor treatment. The immunosuppressant in the mRNA dosage form comprises one or more of an mRNA that encodes a CTLA-4 inhibitor, an mRNA that encodes a PD-1 inhibitor, and an mRNA that encodes a PD-L1 inhibitor; after the immunosuppressant in the mRNA dosage form is transfected into cells, the transfected cells can express the corresponding inhibitors of CTLA-4, PD-1 and PD-L1 proteins, and has the function of corresponding protein inhibitors; and the immunosuppressant in the mRNA dosage form can significantly reduce tumor sizes, and can significantly increase the proportion of CD8+ in tumor-infiltrating T cells. Compared with immunosuppressants in a protein dosage form, the immunosuppressant in the mRNA dosage form has the advantages of low immunogenicity, long in vivo half-life, and low costs.
More Like This:
Inventors:
HU YONG (CN)
ZHANG MIAOMIAO (CN)
HONG DAN (CN)
HU XUN (CN)
ZHANG MIAOMIAO (CN)
HONG DAN (CN)
HU XUN (CN)
Application Number:
PCT/CN2020/134461
Publication Date:
June 16, 2022
Filing Date:
December 08, 2020
Export Citation:
Assignee:
SHENZHEN RHEGEN BIOMEDICAL TECH CO LTD (CN)
International Classes:
A61K48/00; A61K31/7088; A61P35/00; A61P37/06
Domestic Patent References:
| WO2017020026A1 | 2017-02-02 | |||
| WO2020056304A1 | 2020-03-19 |
Foreign References:
| CN110505877A | 2019-11-26 | |||
| CN108430456A | 2018-08-21 | |||
| CN109476718A | 2019-03-15 | |||
| CN109562153A | 2019-04-02 | |||
| CN111821433A | 2020-10-27 |
Attorney, Agent or Firm:
BEIJING GAOWO LAW FIRM (CN)
Download PDF: